Serum CGRP in migraine patients using erenumab as preventive treatment

Aim Serum levels of Calcitonin Gene-Related Peptide (CGRP)-like immunoreactivity (CGRP-LI) in migraine patients before and after starting treatment with erenumab were measured to evaluate the association with clinical treatment response. Methods Blood samples were collected from the cubital fossa be...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of headache and pain Ročník 23; číslo 1; s. 120 - 7
Hlavní autoři: de Vries Lentsch, Simone, Garrelds, Ingrid M., Danser, A. H. Jan, Terwindt, Gisela M., MaassenVanDenBrink, Antoinette
Médium: Journal Article
Jazyk:angličtina
Vydáno: Milan Springer Milan 01.12.2022
Springer Nature B.V
BMC
Témata:
Calcitonin
Calcitonin gene-related peptide
CGRP
Headache
Immunoreactivity
Internal Medicine
Medicine
Medicine & Public Health
Migraine
Monoclonal antibodies
Neurology
Pain Medicine
Patients
Peptides
Radioimmunoassay
Regression analysis
Serum
Serum levels
Monoclonal antibodies
Serum
CGRP
Migraine
ISSN:1129-2369, 1129-2377, 1129-2377
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Aim Serum levels of Calcitonin Gene-Related Peptide (CGRP)-like immunoreactivity (CGRP-LI) in migraine patients before and after starting treatment with erenumab were measured to evaluate the association with clinical treatment response. Methods Blood samples were collected from the cubital fossa before (T0) and 2–4 weeks after (T1) starting treatment with erenumab. Clinical response was monitored using a daily headache e-diary. Serum levels of CGRP-LI, assessed using radioimmunoassay, were compared between T0 and T1, correcting for migraine reduction. In addition, for both T0 and T1, linear regression models were constructed using migraine reduction as outcome and serum CGRP-LI as independent variable, corrected for age, gender and monthly migraine days (MMD) at baseline. Results Serum CGRP-LI did not differ between T0 and T1 ( p  = 0.30). However, there was an interaction between time and reduction in MMD ( p  = 0.01). Absolute reduction in MMD in the third month after treatment with erenumab was associated with serum CGRP-LI at T1, 2–4 weeks after starting treatment with erenumab ( p  = 0.003), but not with serum CGRP-LI at T0 ( p  = 0.24). Conclusion Lower serum CGRP-LI 2–4 weeks after starting treatment with erenumab was associated with a higher reduction in migraine days after three months of treatment. Although the underlying mechanisms remain to be determined, this suggests that changes in CGRP levels, shortly after starting erenumab, are important for its clinical effect. Highlights • Lower serum levels of calcitonin gene-related peptide (CGRP)-like immunoreactivity (CGRP-LI) in migraine patients at 2–4 weeks after starting treatment with erenumab were associated with better treatment response after three months. • Early changes in serum CGRP may be important for the clinical effect of erenumab in migraine.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1129-2369
1129-2377
1129-2377
DOI:10.1186/s10194-022-01483-z